Stock comparison
Haemonetics
Ligand Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
LGND
Ligand Pharmaceuticals
Market cap
$4.6B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | LGND | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 55D | HAE |
| Benjamin Graham | 85A | 67D | HAE |
| Philip Fisher | 60C | 64C | LGND |
| Peter Lynch | 54C | 54C | Tie |
| Joel Greenblatt | 31F | 53D | LGND |
| Charlie Munger | 54D | 57D | LGND |
| Terry Smith | 55D | 47D | HAE |
Side-by-side metrics
| Metric | HAE | LGND |
|---|---|---|
| Market cap | $2.98B | $4.6B |
| P/E (TTM) | 24.8x | 27.6x |
| EV/EBIT | 14.1x | 97.7x |
| ROIC (TTM) | 8.37% | 5.61% |
| Gross margin | 55.74% | 98.61% |
| Net margin | 7.29% | 55.95% |
| Revenue CAGR 5y | 7.65% | 2.64% |
| EPS CAGR 5y | 24.62% | 16.8% |
| Debt / Equity | 1.5x | 0.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 97.7x+86%
- Revenue CAGR 5y7.65%vs 2.64%+66%
- ROIC (TTM)8.37%vs 5.61%+33%
- EPS CAGR 5y24.62%vs 16.8%+32%
LGND leads on
- Net margin55.95%vs 7.29%+87%
- Debt / Equity0.5xvs 1.5x+71%
- Gross margin98.61%vs 55.74%+43%
- Market cap$4.6Bvs $2.98B+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.